Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

We recently published a list of Dividend Stock Portfolio For Income: Top 10 Stocks to Buy. In this article, we are going to ...

I always find myself rooting not necessarily for the actor who gave the best performance — because, really, who can say which ...

The FDA accepted a supplemental biologics license application for Opdivo plus Yervoy as a first-line treatment for some adult ...

Healthcare is considered a defensive industry, since good medical care is needed regardless of economic or market conditions.

MONECO Advisors LLC significantly increased its holdings in Bristol-Myers Squibb during the fourth quarter, nearly doubling ...

Eli Lilly releases cheaper vials of the weight-loss drug for self-paying patients and cuts the price of two existing doses.

William Blair analysts have lowered their FY2027 earnings per share estimate for Bristol-Myers Squibb from $7.70 to $6.50.

This was the stock's fifth consecutive day of gains.

Looking for undervalued stocks? We identified the top undervalued stocks in March 2025. Check out the list here.

Bristol Myers' Opdivo plus Yervoy gets FDA Priority Review for first-line MSI-H/dMMR metastatic colorectal cancer, with a ...

Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a ...